Post by Gill Sawhney

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T cell therapy developed by Carl June, that would go on to become the first such treatment approved by the FDA—were still alive without a lymphoma relapse, according to long-term follow-up data published in the New England Journal of Medicine by researchers from the Abramson Cancer Center and the Perelman School of Medicine. In the analysis of 38 patients from a phase II clinical trial (including 24 patients with large B-cell lymphoma and 14 with follicular lymphoma) conducted at Penn Medicine’s Abramson Cancer Center, no patients experienced a relapse after 5.4 years, and most relapses occurred within the first year after CAR T cell infusion, supporting the hypothesis that patients who experience a long-term response to CAR T cell therapy may be cured. #CAR #CART #UniversityofPennsylvania #UPenn #PennMedicine #celltherapy